AZD7762: The Future of Cancer Therapy? #sciencefather #AZD7762
AZD7762 is a potent checkpoint kinase 1 (Chk1) inhibitor designed to enhance the efficacy of DNA-damaging therapies like chemotherapy and radiation by disrupting cancer cells' ability to repair DNA. By inhibiting Chk1, AZD7762 abrogates the G2/M cell cycle checkpoint, leading to increased DNA damage, mitotic catastrophe, and apoptosis in tumor cells. Preclinical studies have demonstrated its potential in sensitizing various cancers—including triple-negative breast cancer, urothelial carcinoma, osteosarcoma, and pancreatic cancer—to agents like gemcitabine, cisplatin, and radiation .
Visit Our Website : http://biotechnologyscientist.com
Contact Us : support@biotechnologyscientist.com
Nomination Link : https://biotechnologyscientist.com/award-nomination/?ecategory=Awards&rcategory=Awardee
#AZD7762
#Chk1Inhibitor
#CancerTherapy
#DNARepair
#MitoticCatastrophe
#TripleNegativeBreastCancer
#UrothelialCarcinoma
#Osteosarcoma
#PancreaticCancer
#Gemcitabine
#Cisplatin
#RadiationTherapy
#CellCycleCheckpoint
#Apoptosis
#Cardiotoxicity
#BAG3
#TargetedTherapy
#OncologyResearch
#PrecisionMedicine
#ClinicalTrials
Comments
Post a Comment